Bicara Therapeutics Inc. Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Bicara Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q3 2025.
  • Bicara Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$36.3M, a 108% decline year-over-year.
  • Bicara Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$122M, a 104% decline year-over-year.
  • Bicara Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$68M, a 30.8% decline from 2023.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Bicara Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$122M -$36.3M -$18.8M -108% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$103M -$27.4M -$10.3M -60.6% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-10
Q1 2025 -$92.3M -$36.8M -$24.3M -195% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-10
Q4 2024 -$68M -$21M -$8.52M -68.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 -$59.5M -$17.5M +$5.36M +23.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$64.8M -$17M -$7.76M -83.6% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-10
Q1 2024 -$57.1M -$12.5M -$5.1M -68.8% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-10
Q4 2023 -$52M -$12.4M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 -$22.8M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$9.29M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$7.41M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12

Bicara Therapeutics Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$68M -$16M -30.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 -$52M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.